News
First place awarded to Pantherics at Healthcare Innovation Pitch Event
Pantherics Incorporated is pleased to receive the first place and $20,000 prize in the Healthcare Track of the Healthcare Innovation Pitch Event during Milwaukee Tech Week (Oct 3-7, 2022). Dr. Douglas Stafford, Pantherics CEO, presented […]
Pantherics Receives SBIR funding from the NIH to advance new drug development
Pantherics Incorporated received a $255,841 Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute, to advance development of a fundamentally novel anti-inflammatory drug, […]
Pantherics awarded Phase II Bridge Grant from UWM Research Foundation
Milwaukee, WI (April 27, 2022). The University of Wisconsin (UWM) Research Foundation (RF) announced a $38,000 Phase II Bridge Grant award to Pantherics Incorporated following their recent competition. The Bridge Grant Program bolsters efforts to […]
Both enantiomers of PI-301 are almost equally active with similar DMPK
MIDD0301 is being developed as an oral drug to relax airway smooth muscle (ASM) and reduce lung inflammation in asthma. We report a comparative study of MIDD0301 and its S isomer (MIDD0301S), and found that […]
Detailed metabolism of PI-301 described in recent publication
Background: PI-301 is an oral asthma drug candidate that binds GABAA receptors on airway smooth muscle and immune cells. Objective: The objective of this study is to identify and quantify PI-301 metabolites in vitro and […]
Pantherics received UWM Research Foundation Bridge Award
Pantherics received a Phase I Bridge Award from the University of Wisconsin-Milwaukee Research Foundation (UWM-RF) to advance clinical trial planning for its lead drug candidate PI301 (aka MIDD0301). Pantherics holds a worldwide, exclusive license to […]
New publication describing the reduction of airway hyperresponsiveness with nebulized PI301
Pantherics just published a new study investigating the effect of nebulized PI-301 in moderate and severe murine asthma models. The work has been published in ACS Pharmacology and Translation Science titled: Nebulized MIDD0301 Reduces Airway […]
Pantherics Incorporated receives the STTR grant from the National Heart, Lung and Blood Institute.
Pantherics Incorporated received a $224,756 Phase I Small Business Technology Transfer (STTR) grant from the National Institutes of Health (NIH) to advance research on a fundamentally novel asthma control drug. The first-in-class drug, MIDD0301, was discovered by […]
Pantherics Incorporated merged with BIO33 Degrees, Inc.
The Wisconsin startup company, Pantherics Incorporated, merged last month with San Diego based Bio33 Degrees, Inc., creating a unified drug discovery and development platform to target GABAAR in peripheral tissues. Lead therapeutic programs address unmet […]